


Kaiser Permanente Study[†]

No Pattern in Discontinuation Rate by Diagnosis

	<u>Sample Size</u>	<u>No. (%) With Lovastatin Use Before Index Date</u>	<u>No. (%) With Lovastatin Use After Index Date</u>	<u>% Discontinued</u>
Liver disease & 2+ LT abn.	6391	2746 (43)	2399 (38)	12.6
Liver disease only	6963	2654 (38)	2181 (31)	17.8
≥2 LT abn. only	33379	21102 (63)	16101 (48)	23.7
≥1 LT abn. only	100496	51079 (51)	42216 (42)	17.4
No diagnosis or LT abn.	294017	115043 (39)	96353 (33)	16.2

[†] Accepted by *Drug Safety* Sep-2007.

MEVACOR™ OTC Use Over Time in Study 076 (N=722)



Over 33,000 CHD Events Prevented in 10 Years in Population of One Million Based on CUSTOM Versus No Treatment

Risk Strata	Fraction of CUSTOM Users in Stratum	Predicted Events in Untreated CUSTOM Users	Events Prevented With OTC Lovastatin
0–5% (2.5%)	0.29	7,250	1,812
5–10% (7.5%)	0.19	14,250	3,562
10–20% (15%)	0.28	42,000	10,500
20–25% (22.5%)	0.04	9,000	2,250
>25% (30%)	0.03	9,000	2,250
Pre-existing condition* (30%)	0.17	51,000	12,750
Total	1.00	132,000	33,124

* Established CHD, stroke, diabetes.
 Events prevented based on 25% RRR.
 (Data): 10-year risks used for calculations in each stratum.
Am J Cardiol 2006;97:851-856.

Total-C Package

Decision Tree

You must follow the chart below to see if this product is right for you.

This product is **ONLY** for people who meet **ALL OF THE REQUIREMENTS** listed below. If you do not meet **ALL OF THE REQUIREMENTS**, you should not use this product without talking to a doctor.

